BSX · Earnings call · 2026Q3T · Full report
Operating Cash Flow and Capex
BOSTON SCIENTIFIC CORP · 2026-10-28 · Importance 51 · Surprise 24 · In source text
Q3 free cash flow was $867 million, comprising $1.05 billion of operating cash flow less $180 million of net capital expenditures. Management expects full-year 2026 free cash flow of approximately $3.6 billion, reflecting a reduced operating-income outlook.
Key facts
- Boston Scientific expects FY2026 free cash flow of approximately $3.6 billion, reflecting a reduced operating-income outlook.
- Q3 2026 free cash flow was $867 million, comprising $1.05 billion of operating cash flow less $180 million of net capital expenditures.
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| cash | negative | committed | — | Boston Scientific expects FY2026 free cash flow of approximately $3.6 billion, reflecting a reduced operating-income outlook. |